|Home | About | Journals | Submit | Contact Us | Français|
We recently identified Rbm24 as a novel gene expressed during mouse cardiac development. Due to its tightly restricted and persistent expression from formation of the cardiac crescent onwards and later in forming vasculature we posited it to be a key player in cardiogenesis with additional roles in vasculogenesis and angiogenesis.
To determine the role of this gene in cardiac development, we have identified its zebrafish orthologs (rbm24a and rbm24b), and functionally evaluated them during zebrafish embryogenesis. Consistent with our underlying hypothesis, reduction in expression of either ortholog through injection of morpholino antisense oligonucleotides results in cardiogenic defects including cardiac looping and reduced circulation, leading to increasing pericardial edema over time. Additionally, morphant embryos for either ortholog display incompletely overlapping defects in the forming vasculature of the dorsal aorta (DA), posterior caudal vein (PCV) and caudal vein (CV) which are the first blood vessels to form in the embryo. Vasculogenesis and early angiogenesis in the trunk were similarly compromised in rbm24 morphant embryos at 48 hours post fertilization (hpf). Subsequent vascular maintenance was impaired in both rbm24 morphants with substantial vessel degradation noted at 72 hpf.
Taken collectively, our functional data support the hypothesis that rbm24a and rbm24b are key developmental cardiac genes with unequal roles in cardiovascular formation.
During vertebrate embryogenesis the heart is the first organ to develop and achieve functionality. Model organism studies have uncovered a number of genes such as Nkx2.5, which have important functions in early vertebrate myocardial development and differentiation [1,2]. Despite an increasing body of data illuminating the roles played by several key genes during cardiac development, there is still much to learn about what other factors may be critical. The general stages of cardiac development are invariable throughout vertebrate model organisms where heart development has been examined, with zebrafish progressing through these stages at a particularly rapid rate . During zebrafish cardiogenesis the heart cone is the first structure to form between 19-20 hpf, followed by the formation of a short cardiac tube lacking discrete chambers by 24 hpf. Subsequently the cardiac tube lengthens and distinct ventricle and atrium chambers are discernable by 30 hpf with heart tube looping occurring around 36 hpf. A functional two chambered zebrafish heart is visible by 48 hpf .
In a recent transcriptional profiling study, we compared the signatures of mouse embryonic stem cells as they were differentiated towards cardiac cell fates in an effort to uncover novel critical cardiac genes. In this initial study we described the cardiac developmental expression of 31 identified candidate genes with previously unknown roles in cardiogenesis. Furthermore, nine of these transcripts were expressed in the forming cardiac crescent of the mouse embryo , consistent with roles in the earliest stages of heart development. Based on the early cardiac expression of these genes we predicted they likely play significant roles in heart development.
In this paper we report functional evaluation of one of these genes, Rbm24, through the identification, characterization and knockdown of its zebrafish (Danio rerio) orthologs. Rbm24 is a member of the RNA binding protein family, based upon the identification of a RNA recognition motif (RRM) in amino acid residues 12-84. RRMs are the most common and best characterized RNA binding modules with many functioning in most post-transcriptional processes . The RRM is composed of four-stranded anti-parallel β-sheets with two helices packed against it such that the domain has the split αβ (βαββαβ) topology . Often, RRMs function in concert to increase binding specificity possibly because the number of nucleotides recognized by a single RRM is generally too small to define a unique binding sequence . RRMs are found in a variety of RNA binding proteins, including several hnRNP proteins, proteins implicated in regulation of alternative splicing, and protein components of snRNPs indicating a diverse role of these motifs in cellular development and function.
As we have shown previously, the mouse Rbm24 transcript is upregulated in the cardiac progenitor population and is expressed from the earliest stages of cardiac specification, in the cardiac crescent, and subsequently within the heart tube and looping heart . Based upon these observations we hypothesized that Rbm24 plays a crucial role in cardiogenesis. In this study we investigated the putative role of Rbm24 in cardiac development. We have identified two rbm24 zebrafish orthologs (termed rbm24a and rbm24b), and demonstrate that their spatial expression is consistent with our observations in mice. We use rbm24a and rbm24b translation blocking morpholino antisense oligonucleotides (MO) in the early embryo and demonstrate that each zebrafish rbm24 ortholog has a key but unequal role to play in cardiac development. Additionally, we demonstrate a role for rbm24a and rbm24b in normal vascular development. Vascular development consists of vasculogenesis which is the de novo formation of the first vascular vessels and subsequently angiogenesis which is the formation of additional vasculature as extensions of existing vasculature. Zebrafish vasculogenesis results in the formation of the main trunk vessels with the DA first to form (24 - 26 hpf) followed by the CV and PCV (28 - 30 hpf) and several heart vessels generating the first single circulation loop. Angiogenesis can be observed in the trunk by 24 hpf as intersegmetal vessels (Se) begin to form as paired dorsally extending branches off the DA and subsequently off the PCV (~32 hpf). As the Se reach the dorsal line of the embryo the ends of the vessels form connections resulting in two dorsal longitudinal anastomotic vessels (DLAVs) running along the anterior-posterior (A-P) axis of the embryo at the dorsal line. By 48 hpf these trunk vessels are fully formed with circulation [9,10]. Our findings show the requirement for rbm24a and rbm24b in cardiac development and vasculogenesis with a more pronounced role for rbm24a, and an additional putative role for rbm24a in angiogenesis.
We recently reported the identification of Rbm24 as one of a number of novel transcripts discretely expressed in the earliest stages of cardiac development in the mouse embryo . To facilitate determination of the biological requirement for this gene during vertebrate embryonic development, we first set out to identify the orthologous gene/s in zebrafish. In the transition between assembly Zv8 and Zv9 of the zebrafish genome, first one and then a second putative rbm24 ortholog was identified. The current assembly (Zv9) identifies a protein coding gene as rbm24a residing on chromosome 19 and also a novel annotation of a putative rbm24b protein coding gene residing on chromosome 16. To confirm the validity of these most recent changes to the genome annotation we compared these findings to our own comparative genomic analyses.
The first annotated rbm24a gene encodes a protein that displays strong similarity to the mouse Rbm24 (E-value = 3e-90; 188/237 (79%) amino acids). Using the mouse Rbm24 as a blastp query to search the NCBI RefSeq database of D. rerio proteins we detected strong similarity (E-value = 5e-61; 103/116 (88%)) to a hypothetical protein LOC562236 encoded by a gene (zgc:136803) on chromosome 16 (Zv8). This protein is now termed rbm24b in Zv9. The identification of these genes as rbm24 orthologs is further supported by the identification of a pair of annotated rbm24 paralogs in both the medaka (Oryzias latipes; chr. 11, 16) and pufferfish (Tetraodon nigroviridis; chr. 21 and 8) genomes. Zebrafish chromosome 19, where rbm24a resides, shares a common evolutionary origin with O. latipes chromosome 11 and T. nigroviridis chromosome 21 . Similarly, chromosomes 16 and 8 in O. latipes and T. nigroviridis, respectively, map to the rbm24b region of chromosome 16 in D. rerio.
The spatial and temporal expression of both rbm24 orthologs was determined using RNA in situ hybridization (ISH) (Figure (Figure1).1). Both rbm24 orthologs show cardiac expression early in development. At 15.5 hpf we detected rbm24a but not rbm24b expression in myocardial precursor cells (Figure (Figure1B1B and and1C).1C). By 24 hpf both rbm24a and rbm24b expression was detected in the forming heart (Figure (Figure1E1E and and1F).1F). Expression of rbm24a was also detected in the lens of the eye. By 48 hpf, and continuing through 72 hpf, rbm24a and rbm24b exhibit broad expression throughout the heart, although expression of rbm24a was higher in the atrium than the ventricle. By contrast expression of rbm24b appeared uniformly expressed in both heart chambers (Figure (Figure1I1I and and1L).1L). These data are consistent with cardiac expression of the mouse Rbm24 ortholog, and suggest incompletely overlapping requirements for rbm24a and rbm24b during zebrafish cardiac development.
By 72 hpf both rbm24a and rbm24b show incompletely overlapping vascular expression in addition to cardiac expression. rbm24a is expressed in the DA and intestinal vasculature (IV) while rbm24b is expressed in the PCV as well as the IV (Figure (Figure1N1N and and1O).1O). The early expression of both rbm24a and rbm24b in both the heart and vasculature suggests potentially important roles in cardiogenesis and vasculogenesis.
To determine the functional role of the rbm24 orthologs in cardiac and vascular development, translation blocking morpholino antisense oligonucleotides (MO) were designed against the 5' UTR of each transcript. The effects of gene knockdown was assessed for each ortholog individually post microinjection of either MO into zebrafish embryos at the 1-2 cell stage. Titration experiments were conducted to determine MO quantities sufficient to induce a consistent phenotype in a majority of embryos injected (Additional File 1). Injection of 5 ng of rbm24a MO or 8 ng rbm24b MO resulted in a robust cardiac phenotype for a significant number of injected embryos at 48 hpf (64/67 and 59/62 respectively) (Table (Table1),1), compared to uninjected embryos (Figure 2A, B and and2D).2D). During cardiogenesis the heart tubes of all affected morphant embryos failed to correctly loop, remaining linear but with distinct ventricular and atrial chambers (Figure (Figure2).2). Affected embryos also exhibited reduced blood circulation, which led to cardiac edema in all cases by 48 hpf and continually worsened as development progressed (Additional File 2, 3, 4, 5, 6, 7, 8, 9, 10). A subset of rbm24a MO treated embryos (6/64) displayed an even more severe phenotype, lacking a distinct heart tube and exhibiting a beating focus of periodically contracting cells. This poorly organized cardiac structure was located ventral to the embryo between the embryo and the yolk suggesting a defect in the migration and organization of the cardiac fated cells. Similarly reduction of rbm24a or rbm24b expression using splice blocking morpholinos, designed against the second intron/exon boundary, also resulted in cardiac looping defects and cardiac edema in a majority of embryos (92.7% and 54.4% respectively) (Additional File 11). Knockdown efficiency was evaluated by RT-PCR for embryos displaying cardiac looping defects and cardiac edema after injection with splice blocking morpholino. Both rbm24a and rbm24b transcript levels were significantly reduced to 42.80% +/- 3.35, P < 6.5 × 10-4 and 40.27% +/- 3.19, P < 4.4 × 10-5 of transcript levels in respective uninjected controls (Additional File 12). We used translation blocking MO in all subsequent MO-based experiments due to their greater efficacy.
To confirm the phenotype observed in the rbm24 morphants was not due to non-specific morpholino toxicity, embryos were co-injected with p53 morpholino and rbm24a MO or rbm24b MO (Methods). The cardiac phenotypes remained unchanged in the presence of the p53 morpholino (Additional File 13). We then performed phenotype rescue for both rbm24 morphants to determine the sequence specificity of the observed morphant phenotypes. We generated full length capped poly-A RNA transcripts for each ortholog and co-injected each along with the respective rbm24 MO, directed against the 5'UTR not present in the in vitro transcribed RNA. Rescue for rbm24a MO was achieved with 800 pg of RNA (36/45) while 50 pg of RNA was sufficient for rbm24b MO rescue (35/47). For both orthologs rescue resulted in properly looped hearts, normal systemic circulation and an absence of cardiac edema and by 72 hpf and continuing to 96 hpf (Figure 2F, H, J, K, M and and2P).2P). Taken collectively, these data suggest the phenotype seen with each rbm24 MO is a specific result of reduction in gene expression and support the inference from ISH expression data that both rbm24 orthologs are required for normal cardiac development.
To better evaluate the impact to the heart of reducing rbm24a or rbm24b we assayed the expression of several key myocardial transcripts by ISH, including myosin light polypeptide 7, myl7 (heart), myosin heavy polypeptide 6, myh6 (atrium) and ventricular myosin heavy chain, vmhc (ventricle). Expression of each marker was evaluated in control (uninjected), rbm24a MO and rbm24b MO injected embryos fixed at 72 hpf at which point the zebrafish heart is normally, looped, fully developed and functioning, allowing us to comment in greater detail on the structural deficits contributing to the gross morphological morphant phenotypes. When examining the entire heart, both rbm24a and rbm24b morphant embryos exhibit strong myl7 expression levels comparable to that of controls albeit within an unlooped heart tube. The hearts of controls by contrast are appropriately looped (Figure 3A - F). Additionally in rbm24a morphants defects of the presumptive atrium of the forming heart tube appear more severe than in the ventricular portion (Figure (Figure3C3C and and3D).3D). By contrast organization of the developing ventricle and atrium in rbm24b MO embryos appears equally compromised (Figure (Figure3E3E and and3F).3F). Expression of the atrial marker myh6 for both rbm24 morphants appears qualitatively similar to levels in uninjected controls. Presumptive atria of rbm24a morphant heart tubes appear linear and truncated, while to rbm24b morphants also have linear longer heart tubes, both contrasting with the looped atrium observed in uninjected controls (Figure 3G - L). These data are consistent with the observations that rbm24a expression was higher in the atrium than the ventricle by 72 hpf, contrasting with the more uniform expression observed for rbm24b across both heart chambers (Figure (Figure11).
Both rbm24 morphant conditions exhibited a near abrogation of the levels of the ventricular marker vmhc compared to strong expression in uninjected controls (Figure (Figure3M3M - -3R).3R). In rbm24a MO morphants expression of vmhc was faint but with expression clearly bounded to the heart tube with a clear ventricular portion; however, the expression uncharacteristically extended beyond the ventricular portion into the presumptive atrium of the heart tube (Figure (Figure3O3O and and3P).3P). For rbm24b morphants vmhc expression was very diffuse and failed to clearly mark a ventricular boundary. These findings for vmhc expression were unexpected; both in the reduction of total expression seen for both rbm24 morphants and the apparent stronger severity of the ventricular phenotype compared to the atrial phenotype for both rbm24 morphants. Taken together the expression of these markers highlight the differential spatial impact of each rbm24 ortholog in heart structure development of the myocardium, and is consistent with our previous gross morphological observations. These data indicate an incompletely overlapping role for rbm24a and rbm24b in heart tube formation and subsequent heart looping.
The observed cardiac edema may result from reduced circulation as a consequence of defects in heart structure, heart rate, aberrant vasculature or combinations of these factors. Given the observed structural defects, we additionally assayed heart rate as a potential contributor to cardiac edema in the rbm24a MO and rbm24b MO injected embryos . Heart rate counts were determined for uninjected, rbm24a MO and rbm24b MO injected embryos (n = 50) at 48, 72 and 96 hpf. At 48 hpf both rbm24a and rbm24b morphants displayed significantly lower heart rate compared to uninjected controls (P < 0.0002) (Figure (Figure4).4). Heart rates in rbm24a MO injected embryos remain significantly lower than uninjected controls at 72 hpf and 96 hpf. By contrast the heart rate of rbm24b MO injected embryos recovered such that it did not differ significantly from uninjected controls at 72 hpf and 96 hpf (P > 0.12) despite their continued structural anomalies. These data demonstrate cardiac edema is not ameliorated in rbm24b morphants despite heart rates increasing to normal levels, suggesting the role of other factors must be considered as contributing to compromised circulation. Although defects in structure and rates of contraction may contribute to compromised circulatory function, we posit that vascular disruption likely also plays a role in the resulting edema.
To determine the functional role of rbm24a and rbm24b in vascular development we also undertook MO-based analyses of each ortholog in the TG(kdrl:G-RCFP) transgenic zebrafish reporter line which fluorescently marks all endothelial cells highlighting the forming cardiovascular structures . Embryos were examined for vascular expression, after injection of rbm24a MO or rbm24b MO as described above, after heart formation and completion of vasculogenesis at 48 and 72 hpf (Figure (Figure5).5). As per our earlier experiments, morphant embryos for both genes exhibit endocardial cardiac edema and a lack of heart looping displaying little to no circulation with 30/31 and 45/50 embryos displaying cardiac defects for rbm24a and rbm24b morphants respectively (Figure 5D - F and 5M - O). Additionally, all rbm24a and rbm24b morphant embryos display a reduction in total trunk vasculature and vascular organization in 100% of the embryos (Figure 5G - I and 5P - R); however vasculogenic and angiogenic vessels are disrupted to differing degrees. At 48 hpf rbm24a morphants posses a clearly present PCV appearing thicker than normal with no detectable DA or CV (Figure (Figure5H).5H). Angiogenesis is severely disrupted in these embryos with unpaired stunted dysmorphic Se also appearing thicker extending only to the midline of the embryo and thus a complete lack of DLAVs. By contrast the rbm24b morphant at 48 hpf shows little to no disruption of the DA, a visible but malformed CV and no detectable PCV (Figure 5 I). Unlike rbm24a morphants, rbm24b morphants have less disruption of angiogenesis. Se in rbm24b morphants display pairing at the posterior end of the embryo and extend dorsally the length of the embryo forming one DLAV; however, all these vessels are structurally dysmorphic. Both rbm24a and rbm24b vascular morphant phenotypes become progressively more severe between 48 hpf and 72 hpf. Vessels are less well organized and the number of vessels present is reduced, with no evidence of IV (Figure 5J - L and 5P - R). Of the morphant embryos displaying cardiac defects rbm24a and rbm24b morphants segregated into different classes of vascular defects, with 31/31 rbm24a morphants analyzed possessing disorganized trunk vasculature where Se do not extend the entire dorsal length of the embryo and the DA and CV are undetectable; and 50/50 rbm24b morphants had disorganized trunk vasculature where the Se formed DLAV and yet the PV was undetectable (Figure (Figure5S5S and and5T).5T). These data correlate with respective primary vascular expression locations of rbm24a of DA and rbm24b of PCV and both displaying expression in the IV (Figure (Figure1G1G and and1H).1H). When expression of rbm24a or rbm24b is compromised formation of the vessels required for the initial circulation loop is similarly compromised, likely contributing significantly to the observed cardiac edema in morphant embryos. These findings indicate the endocardium is also compromised as a result of rbm24 knockdown and also suggests that both rbm24a and rbm24b are independently necessary for normal early vascular development and support a putative role for rbm24a in angiogenesis.
To determine whether rbm24a and rbm24b interact genetically in the developing zebrafish embryo, we injected low doses of both rbm24a and rbm24b MOs into the same embryo. Although each MO dosage amount was too low (2.5 ng and 4 ng respectively) to elicit a strong consistent phenotype alone as evidenced by titration experiments (Additional File 1), a much more severe phenotype resulted in the morphants receiving both MOs in concert (Figure (Figure6).6). The double morphants displayed greater cardiac edema at 24 hpf than either morphant alone (Figure 6A - D). By 48 hpf, the double morphants also displayed very little cardiac organization, with most (73/93) failing to form any heart tube structure. No double morphants displayed any circulation (Figure 6E- H). This severe and distinctive phenotype exceeds that observed for either MO when assayed independently, even at the higher concentrations that yield consistent cardiac defects (5 ng of rbm24a MO or 8 ng rbm24b MO). These data support the possibility that roles for rbm24 orthologs may overlap during cardiovascular development.
Rbm24 is a novel cardiac gene candidate identified through transcript profiling of differentiating mESCs . It was initially selected for functional analysis due to its early cardiac expression during mouse development, first detected by in situ hybridization in the cardiac crescent of mice, and subsequently in the heart tube and looping heart.
We integrated syntenic and sequence-based comparative genomic analyses to identify two rbm24 orthologs in zebrafish, establishing that their expression was concordant with our earlier observations in mice. In the zebrafish embryo, a reduction of either rbm24 ortholog expression by injection of morpholinos results in cardiac looping defects and reduced circulation. These embryos later exhibit cardiac edema and distention as early as 48 hpf, but this is likely a secondary effect of reduced rbm24 expression, due instead to reduced circulation . Our data suggests that reduced circulation is likely due to a reduction in critical vasculature and not simply reduced heart rate. Additionally, reduction of either rbm24a or rbm24b independently yielded vascular defects of both myocardium and endocardium. We exclude general toxicity or off target effects as the cause of the observed morphant phenotype by confirming they remain without amelioration in the presence of p53 MO. We also confirmed the morphant phenotypes are sequence-specific by successfully achieving RNA-based phenotype rescue.
Investigation of molecular markers for myocardial development further illuminated the impact of reducing rbm24 expression. Both rbm24 orthologs are detected in the developing heart by in situ hybridization by 24 hpf and sustain expression at least through 72 hpf. In all cases a reduction of rbm24a or rbm24b was sufficient to prevent heart looping noted at 48 hpf and beyond, where normal heart looping occurs at approximately 36 hpf. Expression of rbm24a is unequal between the ventricle and atrium with stronger expression in the atrium while rbm24b shows equivalent expression in both chambers. This skewed expression of rbm24a at higher levels in the atrium is illustrated by truncated and abnormal atrium formation of the developing heart in rbm24a MO injected embryos demonstrating its requirement for cardiogenesis, including atrial specification, at this early stage. A reduction in either rbm24 ortholog severely disrupts the expression level and localization of ventricular marker vmhc yielding little to no expression visible in either rbm24 morphant condition. Reduced ventricular myocardial count disproportionate to the atrium has also been reported with deficient nkx and hedgehog signaling [15,16]. Although reduction of each rbm24 results in incompletely overlapping atrial and ventricular phenotypes, reduction of either is sufficient to compromise the looping of the heart tube. The looping of the heart tube is a result of both genetic and biophysical mechanisms, and perturbation of the mechanical force generated by the contraction of the heart chambers can affect proper heart formation . Zebrafish wea mutants (myh6), display distortions in cardiac looping, but still maintain a functional circulatory system due to the adaptation of the ventricle . This suggests that reduction in rbm24a expression impacts both the ventricle and atrium, likely in the organization or structure of the muscle filaments, in addition to cardiomyocyte count, in turn affecting the ability of the heart to circulate blood.
Although both rbm24a MO and rbm24b MO injected embryos display an additional phenotype of aberrant vascular morphology, with defects in vasculogenesis and angiogenesis the defect in rbm24a morphants appears more severe. The observed phenotypes, however, are also consistent with the exhibited localization of each rbm24 ortholog, wherein rbm24a is expressed in the DA and rbm24b is expressed in the PCV by 72 hpf. The expression difference likely reflects the acquisition of independent roles since duplication of the ancestral gene [19,20], resulting in incompletely overlapping functions for these orthologs in vasculogenesis. Angiogenesis is impaired when expression of either rbm24 ortholog is reduced. The integrity of these first vessesls of angiogenesis (Se and two DLAVs) deteriorates over time. In rbm24a morphants Se are more severely affected not reaching the dorsal line to form DLAVs at 48 hpf and continue to deteriorate by 72 hpf. This may result form the lack of any discernable DA. rbm24b morphants still possessed a visible DA but no PCV, Se and one DLAV were present and only displayed mild morphology alterations at 48 hpf with subsequent severe deterioration by 72 hpf. In the case of all rbm24 morphants there is an inability to maintain the new vessels formed during angiogenesis and a wasting of any vessels resulting from vasculogenesis. It is unclear the molecular basis of this blood vessel deterioration. Normal rbm24 expression may be playing a direct role in the vascular maintenance or the angiogenesis pathway. Also to be considered is that a lack of sufficient concentrations of growth factors and mitogens due to insufficient circulation may be preventing maintenance of initiated vasculature, since it has been shown Se sprouting and extension involves several rounds of cell division  and vegfA is required for vascular maintenance .
The incompletely overlapping role of rbm24a and rbm24b in the developing heart and vasculature is underscored by the extreme phenotype observed in the double morpholino injections. rbm24a and rbm24b appear to act in parallel in cardiac development, converging on a common phenotype for which they are both overtly required. By contrast in vasculogenesis, rbm24a and rbm24b appear to function in parallel but differentially in artery and vein formation, resulting in different vascular phenotypes which are individually sufficient to disrupt formation of the initial embryonic circulation loop. Further analyses will be required to determine the mechanistic role played by rbm24a/b and whether their roles involve one or all of the above-discussed mechanisms.
The critical role for rbm24 in cardiogenesis raises the question whether mutations at the orthologous human locus may contribute to cardiac disorders. Interestingly, Wessels et al. recently identified a novel cardiac syndrome with noncompaction cardiomyopathy, bradycardia, pulmonary stenosis, atrial septal defects, and heterotaxy with genetic linkage to human chromosome 6p . Genome-wide linkage analysis localized the implicated interval to chromosome 6p24.3-21.2, a region encompassing the human RBM24 ortholog (6p22.3), making it an ideal candidate for variation underlying this phenotype. However, sequencing of all RBM24 coding exons, intron/exon boundaries and the upstream promoter region in two affecteds, revealed only known polymorphisms (rs10456798 and rs35860841) that were also observed in a heterozygous state in an unaffected family member. While we can exclude a role for RBM24 coding mutations, additional sequencing of putative regulatory sequences will be necessary to determine if RBM24 may play a role in this syndrome.
Our data provide significant insight into the role of rbm24 in formation of cardiac and vascular systems, however much remains to be learned about the exact mechanism by which it functions and the role RBM24 may play in human disease. Other RRM containing proteins have also been shown to serve important roles in embryonic development [24,25] and post-transcriptional regulation is a frequent theme. With this in mind, we hypothesize that the protein plays a role in the post-transcriptional regulation of gene expression important for cardiac and vascular development. In the case of rbm24a and rbm24b depletion for instance, we found that expression of the ventricular marker vmhc is nearly abolished in the heart at 72 hpf, suggesting they both may contribute to specific regulation of vmhc mRNA. We will continue elucidate the role and mechanisms of rbm24 function in embryonic development. Furthermore, this study demonstrates the power of the screen that uncovered Rbm24 as a candidate cardiac gene, adding significant value to the original data set for which this work represents just the first of many such analyses awaiting completion.
Adult AB zebrafish were maintained in system water according to standard methods . Embryos were obtained from natural mating of adult fish. All experiments were in accordance with ethical permits by Johns Hopkins Animal Care and Use Committee under protocol number FI10M369.
We used the amino acid sequence of the protein encoded by the mouse Rbm24 gene to perform a blastp query searching the NCBI RefSeq database of D. rerio proteins from the Zv8 2008 genome assembly. Two genes were identified (rbm24 and zgc:136803) which encode proteins displaying strong similarity to the mouse Rbm24 protein (E-value = 5e-61; 103/116 (88%) and E-value = 3e-90; 188/237 (79%), respectively). As of the Zv9 2010 D. rerio genome assembly NCBI RefSeq now annotates the two genes we previously identified as two rbm24 paralogs with protein coding transcripts: rbm24a on chromosome 19 (RefSeq ID: NM_212865) and rbm24b on chromosome 16 (RefSeq ID: NM_001039925).
Total RNA was isolated from whole zebrafish embryos at 24 hpf using TRIzol Reagent and total cDNA was generated with oligo-dT using the SuperScript III First-Strand Synthesis Kit (Invitrogen). Riboprobes for rbm24a, rbm24b, myl7, myh6, and vmhc were generated by PCR amplification of embryo cDNA. PCR fragments were TOPO cloned into PCRII vector (TA Cloning Kit Dual Promoter with pCRII vector, Invitrogen) and transformed into TOP 10 Cells (Invitrogen). Colonies were mini cultured and plasmid DNA was harvested using the QIAprep Spin Miniprep Kit (Qiagen) Digoxygenin-labeled riboprobes were synthesized from 1 μg plasmid DNA using Sp6 and T7 RNA Polymerase (DIG RNA Labeling Kit SP6/T7, Roche), and purified (SigmaSpin Colums, Sigma). Embryos for in situ hybridization at 48 hpf and older were treated with 0.003% 1-phenyl-2-thiourea (PTU) beginning at 48 hpf to reduce pigmentation. Embryos were fixed in 4% paraformaldehyde in PBS overnight at 4°C at 15.5 hpf, 24 hpf, 48 hpf, and 72 hpf; and in situ hybridization was performed as previously described .
Antisense morpholinos for rbm24a and rbm24b were designed and provided by Gene Tools, LLC. The rbm24a translation blocking morpholino (5'-TGCATCCTCACGAAACGCTCAAGTG-3') and the rbm24b translation blocking morpholino (5'-AAATAAACTCCTTGCTCCTTGAAGG-3') were designed to hybridize to the 5' UTR immediately upstream of the translational start site. Morpholinos were diluted with dH2O to 20 ng/nL and titration experiments were conducted at 1, 2, 5 and 10 ng rbm24a MO and 1, 2.5, 5, 7 and 9 ng rbm24b MO to determine an effective dose (n = 100 embryos per concentration). Experimental concentrations of 5 ng rbm24a or 8 ng rbm24b MO were selected and injected into the yolks of 1-2 cell fertilized embryos (n = 75). Double knockdown experiments were conducted with co-injection of 2.5 ng rbm24a and 4 ng rbm24b translation blocking MO into embryos and compared to embryos injected with these amounts of either MO alone. The rbm24a splice blocking MO (5' CGTTATTTGAGATGCCTGACTGTT 3') and the rbm24b splice blocking MO (5' TATTTTGACGTTATTTACCTGGCTG 3') were designed to hybridize to the boundary of the second exon and second intron of the transcript and injected at 7.5 ng and 9 ng respectively. Antisense p53 MO (5'-GCGCCATTGCTTTGCAAGAATTG-3') previously published  was purchased from Gene Tools, LLC and 1 ng was injected into 1-2 cell stage fertilized embryos both with and without each rbm24 translation blocking MO (n = 50) . Embryos were analyzed for cardiac and vascular phenotypes at 48, 72 and 96 hpf.
Total RNA was isolated using TRIzol Reagent (Invitrogen) from whole morphant zebrafish embryos at 24 hpf after injection of either 7.5 ng rbm24a or 9 ng rbm24b splice blocking MO. Total cDNA was generated with oligo-dT using SuperScript III First-Strand Synthesis (Invitrogen). RT-PCR was carried out via the standard curve method on a Bio-Rad DNA Engine Opticon 2 Real-Time Detection System with primers specific to the correctly spliced transcripts at 100 ng input cDNA. Uninjected 24 hpf embryo cDNA was used to generate a standard curve and cDNA from uninjected experimental control embryos was assayed at 100 ng cDNA as the standard for 100% expression. All reactions were run in triplicate at 25 μL volumes using Power Sybr Green PCR Master Mix (1x final) (Applied Biosystems), primers at final concentration 0.08 μM each. Significance of expression reduction was determined using the students t-test statistic comparing transcript levels of rbm24a or rbm24b in uninjected controls to that measured cDNA from their respective morphants.
Total RNA was isolated from whole zebrafish embryos 24 hpf using TRIzol Reagent (Invitrogen) and total cDNA was generated with oligo-dT using SuperScript III First-Strand Synthesis (Invitrogen). Full length rbm24a and rbm24b cDNA were PCR amplified and cloned into the pCR8 gateway vector (pCR8/GW/TOPO TA Cloning Kit, Invitrogen) before being cloned into the pCSDEST destination vector (kindly provided by the lab of Nathan Lawson, UMass Med School). Full length sense capped Poly-A RNA was generated for rbm24a and rbm24b with the mMESSAGE mMACHINE kit (Ambion) and quantified with a NanoDrop 1000. Full length RNA was co-injected into 1-2 cell embryos with rbm24a MO or rbm24b MO at titrating levels and evaluated for phenotype rescue at 48, 72 and 96 hpf. Rescue was confirmed with 800 pg rbm24a RNA and 50 pg rbm24b RNA.
Genomic DNA from two patients and an unaffected family member were included . Direct sequencing of part of the promoter region (1031 bp), all exons plus exon-intron boundaries and a putative regulatory element in intron 3 (1164 bp) of the RBM24 gene was undertaken. Primers were designed to cover all four exons representing the "canonical" sequence (ENST00000379052, transcript length 2,458 bp and 236 aa, http://www.ensembl.org). PCR primers were designed by Primer3 software http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi and are available on request. Amplified PCR products were purified and sequenced using BigDye Terminator chemistry v3.1 on an ABI Prism 3130xl genetic analyzer (Applied Biosystems). Biomedical research involving human subjects has been performed according to the principles of the Helsinki's Declaration. Written informed consents were obtained from the patients and relatives involved in the research. Genomic DNA was taken from patients as per standard care and therefore ethical approval was not required.
Heart rates (beats per minute) were counted for uninjected, rbm24a MO and rbm24b MO injected embryos displaying the morphant phenotype at 48, 72 and 96 hpf. 50 embryos were analyzed per condition per time point. Average heart rates with standard error were plotted and significant heart rate deviation of morphants compared to uninjected controls was determined using the students t-test.
The transgenic zebrafish line TG(kdrl:G-RCFP) generated by Cross and colleagues  was used for vascular expression. Adult fish and embryos were maintained as described . Embryos were injected with either 5 ng rbm24a MO or 8 ng rbm24b MO at the 1-2 cell stage and analyzed at 48 and 72 hpf for G-RCFP expression via fluorescence microscopy.
DA: dorsal aorta; PCV: posterior caudal vein; CV: caudal vein; hpf: hours post fertilization; RRM: RNA recognition motif; MO: morpholino antisense oligonucleotide; ISH: in situ hybridization; Se: intersegmetal vessels; DLAVs: dorsal longitudinal anastomotic vessels.
SM and RM carried out in situ hybridization, morpholino analysis, experimental design and drafted the manuscript, while RM also designed antisense morpholinos. SM additionally conducted heart rate experiments, vascular experiments and assembled the figures and manuscript draft. SB carried out microinjections. DM contributed to in situ hybridization experimental data. MW, BD and AB conducted human RBM24 sequencing experiments on patient samples. ES, JG and SF provided intellectual input and experimental expertise. AM edited the manuscript, provided continuous experimental design, intellectual input and experimental expertise. All authors read and approve the final manuscript.
Translation Blocking MO titrations. Quantitative representation of percentage of embryos displaying cardiac phenotypes achieved from MO titrations. rbm24a MO 1, 2, 5 and 10 ng injected (A). rbm24b MO 1, 2.5, 5, 7 and 9 ng (B). Normal, looped beating heart with no cardiac edema; Class I, looped beating heart with cardiac edema; Class II, unlooped beating heart tube with cardiac edema; Class III, beating heart cell mass with cardiac edema; Dead, extreme cell death and degradation of embryo. n = 100 embryos per concentration.
Uninjected zebrafish heart 48 hpf. Digital video (time-lapse) captured of an uninjected control embryo (lateral) at 48 hpf. Movie demonstrates the looped structure and regular rhythm of the normal heart.
rbm24a MO injected zebrafish heart 48 hpf. Digital video (time-lapse) captured of an rbm24a MO injected embryo (lateral) at 48 hpf. Movie highlights the unlooped (linear) structure of the rbm24a morphant heart displaying edema at this stage in development. Atrial and ventricular chambers are still evident despite structural anomaly; however contraction is slow.
rbm24b MO injected zebrafish heart 48 hpf. Digital video (time-lapse) captured of an rbm24b MO injected embryo (lateral) at 48 hpf. Movie highlights the unlooped (linear) structure of the rbm24b morphant heart displaying edema at this stage in development. Atrial and ventricular chambers are still evident despite structural anomaly.
Uninjected zebrafish heart 72 hpf. Digital video (time-lapse) captured of an uninjected control embryo (lateral) at 72 hpf. Movie demonstrates the looped structure and regular rhythm of the normal heart, with circulation at this stage in development.
rbm24a MO injected zebrafish heart 72 hpf. Digital video (time-lapse) captured of an rbm24a MO injected embryo (lateral) at 72 hpf. Movie highlights the unlooped (linear) structure of the rbm24a morphant heart at this stage in development with cardiac edema. Heart atrial and ventricular chambers are difficult to distinguish and contracting with marked irregularity, with no circulation is detectable.
rbm24b MO injected zebrafish heart 72 hpf. Digital video (time-lapse) captured of an rbm24b MO injected embryo (lateral) at 72 hpf. Movie highlights the unlooped (linear) structure of the rbm24b morphant heart at this stage in development with additional cardiac edema. Atrial and ventricular chambers are still evident but highly distended, with no circulation is detectable.
Uninjected zebrafish heart 96 hpf. Digital video (time-lapse) captured of an uninjected control embryo (lateral) at 96 hpf. Movie demonstrates the looped structure and regular rhythm of the normal heart, with circulation at this stage in development.
rbm24a MO injected zebrafish heart 96 hpf. Digital video (time-lapse) captured of an rbm24a MO injected embryo (lateral) at 96 hpf. Movie highlights the unlooped (linear) structure of the rbm24a morphant heart at this stage in development with extreme cardiac edema. Heart atrial and ventricular chambers are difficult to distinguish and contracting with marked irregularity, with no circulation is detectable.
rbm24b MO injected zebrafish heart 96 hpf. Digital video (time-lapse) captured of severe example of one rbm24b MO injected embryo (lateral) at 96 hpf. Movie highlights the phenotype of the unlooped (linear) highly distended heart of rbm24b morphants at this stage in development, with no detectable circulation. The heart with distinct atrial and ventricular chambers is highly distended and contracting with marked irregularity, with no circulation is detectable.
rbm24a and rbm24b splice blocked morphants display cardiac defects. Injection of 7.5 ng of rbm24a splice blocking morpholino results in a substantial reduction of full-length transcript (A). Injection of 9 ng of rbm24b splice blocking morpholino results in aberrant splicing of the transcript. There is a reduction of full-length transcript 250 bp fragment and appearance of trace amounts of the shortened frameshift fragment 164 bp and shortened in-frame transcript 109 bp (B). RT-PCR measurement of transcript levels show both rbm24a (42.80% +/- 3.35, P < 6.5 × 10-4) and rbm24b (40.27 +/- 3.19, P < 4.4 × 10-5) morphants have significant reduction of transcript levels compared to uninjected controls (C) Error bars are standard deviation, *** P < 0.001.
Supplemental Table 1. Cardiac phenotypes displayed upon knockdown of rbm24a or rbm24b expression via splice blocking morpholino.
p53 MO co-injection does not alter rbm24a and rbm24 morphant phenotypes. Phenotypes were evaluated for embryos post injection rbm24a MO (5 ng) or rbm24b MO (8 ng) alone or in conjunction with p53 MO (1 ng) phenotypes were compared at 48, 72 & 96 hpf. Lateral heart views are shown with a dotted outline around embryo heart chambers. No cardiac phenotype is detected for p53 MO embryos compared to uninjected controls at any time point (A-B, G, H, M, N). At all time points rbm24a morphants maintain unlooped hearts and display cardiac edema in the presence of p53 MO (C, D, I, J, O, P). Morphant phenotype was also maintained between rbm24b morphants in the presence of p53 MO (E, F, K, L, Q, R). v, ventricle; a, atrium; black arrows, cardiac edema.
This study was supported by a grant from the MSCRF (2007-MSCRFE-0205) to ASM and the Johns Hopkins University Institute for Cell Engineering to JDG. SM is supported by funds from the National Institute of Standards and Technology. We thank Colin Huck and the Johns Hopkins FINZ Center for zebrafish husbandry and technical support.